Theragenics Corp (TGX) SEC Filing 10-K Annual report for the fiscal year ending Thursday, December 31, 2009

Exhibit 99.1

Theragenics^® Reports Record Revenue with 2009 Results

$78.3 Million is Highest Annual Revenue in 29-Year History

Pro forma Organic Growth of 10% in Surgical Products Segment for 2009

Supply and Reseller Agreement with Core Oncology adds to Momentum for 2010

BUFORD, Ga.--(BUSINESS WIRE)--February 11, 2010--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008. The terms "Company", "we", "us", or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements.

Highlights

• Recorded consolidated revenue of $18.7 million in the fourth quarter and $78.3 million for the full year.
• Achieved 17% organic revenue growth in our surgical products business for the fourth quarter and 10% pro forma organic growth for the year, compared to 2008.
• EPS for the quarter was $0.01, compared to a loss of $1.89 per share in 2008. Excluding 2008 impairment charges, EPS was $0.01 in the fourth quarter of 2008.
• EPS for the year was $0.09, compared to a loss of $1.77 per share in 2008. Excluding 2008 impairment charges, EPS was $0.13 for 2008.
• Completed the year with cash and cash equivalent of $45.3 million and outstanding borrowings under our credit agreement of $30.3 million for a net positive cash position of $15.0 million.
• Adjusted EBITDA was $13.1 million and cash flow from operations was $11.6 million for 2009.
• In early 2010, we announced a supply and reseller agreement with Core Oncology for our brachytherapy segment. Core is a recognized leader in the brachytherapy industry. We expect Core to represent at least 10% of our brachytherapy segment revenue in 2010.
• Research and Development (“R&D”) expenses increased $860,000 over 2008. This reflects investments to support future growth in the surgical products segment, a strategic initiative that was launched in late 2008.
• Continued our initiative to update and standardize our information technology (“IT”) systems and infrastructure across all of our businesses.
• Purchased a larger facility for increased capacity in our specialty needle manufacturing. We expect to complete improvements and move to this new facility in 2010.
• Capital expenditures were $5.0 million in 2009, reflecting our investments in manufacturing capacity for our surgical products business and in corporate wide IT.